Integrated Community Oncology Network

Jacksonville, Florida 32258

0 studies enrolling now · 32 studies all time

What they study most

Acute Myelogenous Leukemia, Advanced Prostate Cancer, Breast Cancer, Breast Neoplasms, Cancer of the Rectum, Carcinoma, Chemotherapy Side Effects, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Colorectal Cancer, Esophageal Cancer, Esophagus Cancer

Studies at this site

• Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer — Completed
• Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) — Stopped early
• Vinflunine in Hormone Refractory Prostate Cancer (HRPC) — Completed
• 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer — Completed
• Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer — Completed
• Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer — Completed
• Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer — Completed
• BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab — Stopped early
• Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts — Completed
• Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin — Completed
• A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer — Completed
• Low Dose Melphalan and Bortezomib for AML and High-Risk MDS — Completed
• Phase 1 and 2 Study of PX-866 and Cetuximab — Completed
• Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer — Completed
• Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents — Stopped early
• A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer — Completed
• Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site — Completed
• A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) — Completed
• Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) — Completed
• A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — Completed
• A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma — Completed
• Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site — Completed
• Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site — Completed
• Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer — Completed
• Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma — Completed
• Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer — Completed
• Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma — Completed
• Study of XL999 in Patients With Metastatic Renal Cell Carcinoma — Stopped early
• GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer — Stopped early
• DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]) — Stopped early
• Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC. — Status unconfirmed
• Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. — Status unconfirmed